Acadia Q1 revenue $205.8M (+74% YoY), net income $16.6M vs loss year ago

ACADIA PHARMACEUTICALS INC

2024-Q1 EPS reported $0.10 revenue$205,831,000

NUPLAZID net sales $129.9M (+10% YoY); DAYBUE net sales $75.9M (vs $0 in Q1 2023)
Net income of $16.6M ($0.10 EPS) compared to net loss of $43.0M ($0.27 loss) in Q1 2023
Full-year 2024 guidance reiterated: DAYBUE $370-420M, NUPLAZID $560-590M
Cash and investments $470.5M at quarter end, up from $438.9M at Dec 31 2023
Appointed Elizabeth H.Z. Thompson as EVP, Head of R&D

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.6

ACADIA PHARMACEUTICALS INC reported financial results for the three months ended March 31, 2024.

Period: the three months ended March 31, 2024
Result: reported results

Exact text from the filing

On May 8, 2024, Acadia Pharmaceuticals Inc. issued a press release announcing its financial results for the three months ended March 31, 2024.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

ACADIA PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0000950170-24-055647

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.